Key takeaways
- Cagrilintide is a long-acting version of amylin, a hormone that signals fullness, and it works through a different pathway from GLP-1.
- On its own it causes moderate weight loss; its main job is as the partner to semaglutide in CagriSema.
- Cagrilintide alone is not FDA-approved, and the combination is under FDA review with a decision expected around late 2026.
- The papers supplied for this post do not report cagrilintide trial numbers, so this post sticks to what the site entries say.
Most of the weight-medicine conversation has been about GLP-1 drugs. Cagrilintide is interesting because it comes at appetite from a different direction. Novo Nordisk built it mainly to pair with semaglutide, and that pairing is now being reviewed by the FDA.
A note on sources up front: the research papers available for this post are about semaglutide and related drugs, not about cagrilintide itself. For cagrilintide, all we have is the site's entry, which names the phase 2 and REDEFINE trials but does not give their results here. So you won't find trial figures for cagrilintide below.
What amylin does and why a weekly version matters
Cagrilintide is a once-weekly version of amylin, a hormone released along with insulin that signals fullness. Natural amylin doesn't last long in the body. Cagrilintide is a 37-amino-acid modified analog with a C18 fatty diacid attached, which gives it a half-life of about 7–8 days.
It activates amylin and calcitonin receptors in the brain. That increases fullness and slows stomach emptying. Because this is a different pathway from GLP-1, the idea behind combining the two is that they may add to each other rather than overlap.
Semaglutide: the partner with the deepest record
Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic, Wegovy, Rybelsus and the Wegovy pill. Its site entry rates the evidence 5 of 5, with large trial programs (SUSTAIN, STEP, SELECT). SELECT showed a 20% reduction in major cardiovascular events in people with heart disease and overweight.
Researchers keep studying it in more detail. In the FLOW trial of people with type 2 diabetes and chronic kidney disease, fewer serious adverse events were reported with semaglutide than placebo across kidney-function groups. Stopping treatment because of gastrointestinal side effects was more common with semaglutide, 4.5% versus 1.1% 1. That is the kind of detail that makes a long record useful.
For context, in a head-to-head trial summarized in a 2026 comparison, tirzepatide produced more weight loss than semaglutide at week 72 (20.2% vs. 13.7%) 2. The bar for any new combination is therefore set by well-studied drugs.
What the trials are, and what we can't say here
According to the site entry, cagrilintide has a phase 2 randomized trial of the drug alone, and the large phase 3 REDEFINE program includes a cagrilintide-only arm. That puts its evidence at 4 of 5, one step below semaglutide. The entry describes the result for cagrilintide alone as moderate weight loss, and says it adds to semaglutide when combined.
We haven't been given the abstracts of those trials, so we can't report percentages, side-effect rates or how the combination compared with semaglutide alone. If you want those numbers, they are in the trial publications themselves.
How the two compare
| Semaglutide | Cagrilintide | |
|---|---|---|
| What it is | GLP-1 receptor agonist | Long-acting amylin analog |
| FDA status | Approved (Ozempic 2017, Wegovy 2021) | Not FDA-approved |
| Evidence (1–5) | 5 | 4 |
| Half-life | About 7 days | About 7–8 days |
| Banned in sport | No | Yes |
FDA status: ordinary, and not a verdict
Cagrilintide alone isn't approved anywhere. That is the normal position for most compounds. Approval mostly tracks whether a company has paid for large, expensive trials, and many compounds never get that for money reasons, not because anyone showed they don't work.
Here the company did fund big trials, and the combination, CagriSema, is under FDA review with a decision expected around late 2026. Even so, FDA status on its own doesn't tell you whether a compound works. The trial results do. It is also worth knowing cagrilintide is banned in sport.
What real-world experience adds
Cost is a big part of the real-world picture. A 2026 survey of 552 healthcare professionals in South Asia, mostly in India, found that high cost was named as a barrier by 93.8%, and clinicians reported that 51.7% of their patients on newer obesity drugs (semaglutide and tirzepatide) achieved more than 10% weight loss 3. That's a self-reported survey using convenience sampling, so it's a useful look at practice, not proof.
For cagrilintide itself, the supplied material includes no case reports or online-community data, so we won't characterize how people feel about it. As more people use the combination if it's approved, that kind of experience will be worth following, alongside the trials.
The bottom line
Cagrilintide is a thoughtful idea: a weekly fullness hormone that works through a pathway separate from GLP-1. Its trial program is substantial, and the FDA decision on CagriSema is expected around late 2026. For the actual numbers, look to the trial papers.
This is educational information, not medical advice.
Sources
- Safety outcomes of semaglutide by chronic kidney disease severity in the FLOW trial. — Kidney international, Oct 2026. https://pubmed.ncbi.nlm.nih.gov/42901325/
- Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide. — Omics : a journal of integrative biology, Oct 2026. https://pubmed.ncbi.nlm.nih.gov/42902597/
- Perspectives on Newer Antiobesity Drugs (Semaglutide and Tirzepatide) among Healthcare Professionals Treating Obesity in South Asia: A Cross-sectional Survey. — The Journal of the Association of Physicians of India, Sep 2026. https://pubmed.ncbi.nlm.nih.gov/42902646/
